Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)
Conditions
Breast Cancer · Neoplasm, Breast · Breast Diseases · Antihypertensive Agents · Sacubitril/Valsartan · Angiotensin II Type 1 Receptor Blockers · Angiotensin Receptor Antagonists · Molecular Mechanisms of Pharmacological Action · Heart Failure · Cardiac Toxicity · Cancer, Therapy-Related · Cancer Therapy-Related Cardiac Dysfunction · Cardiotoxicity
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Regional Cancer Centre in Opole, Opole, Opole Voivodeship, Poland
Maria Sklodowska-Curie Institute - Oncology Centre (MSCI), Gliwice Branch, Gliwice, Silesian Voivodeship, Poland
Contact: Study coordinator (Michal Jarząb, MD, PhD, Associate Professor) · onkologia@io.gliwice.pl · +48322788886Silesian Center for Heart Diseases, Zabrze, Silesian Voivodeship, Poland
Holy Cross Cancer Centre, Cardio-Oncology Division, Kielce, Świętokrzyskie Voivodeship, Poland
Contact: Study coordinator (Barbara Sosnowska-Pasiarska, MD, PhD) · repikus@poczta.onet.pl · +48 41 34 56 882
Study leads
Mateusz Tajstra
Principal Investigator
3rd Department of Cardiology, School of Medical Sciences in Zabrze, Medical University of Silesia, Katowice; Silesian Center for Heart Diseases